. As gonorrhoea has the ability to develop resistance to antibiotics, consideration should be given to the risk of this infection. Gonorrhoea has already developed a quinolone resistance of greater than 5% (cut off before amending first-line treatment choices); therefore, patients at high risk of this infection should not be prescribed oflaxacin (regimen 2) (BASHH, 2011; Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP, 2013). Ceftriaxone injection is currently the firstline treatment for gonorrhoea (GRASP, 2013), so regime 1 should be used in patients at high risk of this STI (BASHH, 2011).